Literature DB >> 19771536

p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women.

M Meftah El khair1, M M Ennaji, R El kebbaj, R Ait Mhand, M Attaleb, M El Mzibri.   

Abstract

Human papillomavirus (HPV) has been implicated in cervical carcinoma and the p53 gene is polymorphic at amino acid 72 of the protein that it encodes. The association between p53 polymorphisms and risk for HPV-associated cervical cancer has been examined, but the results have been conflicting. It has been reported that patients with the arginine form have a higher risk of developing cervical cancer than those with the proline form. The purpose of this study was to examine whether p53 Arg at the polymorphic position 72 could represents a risk factor for women with high-risk HPV-associated malignant cervical lesions. In this study, the polymorphism was examined by both allele-specific PCR and RFLP analysis in 113 patients with cervical cancer and in 100 healthy controls. There was no statistical difference in the subtype distribution between the cervix cancer and the control groups. There was no significant association between genotype distribution of the p53 codon 72 polymorphism and HPV infection. Thus, polymorphism of the p53 itself as well as in combination with HPV infection may not be a genetic risk for cervical cancer and therefore much attention should be paid to other risk factors such as sexual behavior and smoking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19771536     DOI: 10.1007/s12032-009-9297-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  37 in total

1.  p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women.

Authors:  T Agorastos; A F Lambropoulos; T C Constantinidis; A Kotsis; J N Bontis
Journal:  Eur J Cancer Prev       Date:  2000-04       Impact factor: 2.497

2.  p53 polymorphism and risk of cervical cancer.

Authors:  A Hildesheim; M Schiffman; L A Brinton; J F Fraumeni; R Herrero; M C Bratti; P Schwartz; R Mortel; W Barnes; M Greenberg; L McGowan; D R Scott; M Martin; J E Herrera; M Carrington
Journal:  Nature       Date:  1998-12-10       Impact factor: 49.962

Review 3.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

4.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

5.  P53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the chinese.

Authors:  N M Wang; C H Tsai; K T Yeh; S J Chen; J G Chang
Journal:  Int J Mol Med       Date:  1999-09       Impact factor: 4.101

6.  The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia.

Authors:  Anita Koushik; Anirban Ghosh; Eliane Duarte-Franco; Pierre Forest; Hélène Voyer; Greg Matlashewski; François Coutlée; Eduardo L Franco
Journal:  Cancer Detect Prev       Date:  2005

Review 7.  Viruses in human cancers.

Authors:  H zur Hausen
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

8.  Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs).

Authors:  Mariam Amrani; Khalid Lalaoui; Mohammed El Mzibri; Pedro Lazo; Mohamed Alaoui Belabbas
Journal:  J Clin Virol       Date:  2003-08       Impact factor: 3.168

9.  Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations.

Authors:  Hugo Sousa; Alexandra M Santos; Daniela Pinto; Rui Medeiros
Journal:  Int J Mol Med       Date:  2007-11       Impact factor: 4.101

10.  p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women.

Authors:  W K Baek; J W Cho; S I Suh; M H Suh; D H Shin; C H Cho; T S Lee; S D Cha
Journal:  J Korean Med Sci       Date:  2000-02       Impact factor: 2.153

View more
  6 in total

1.  The preliminary study of p53 codon 72 polymorphism and risk of cervical carcinoma in Gabonese women.

Authors:  Samira Zoa Assoumou; Anicet Luc M Boumba; Angelique Ndjoyi-Mbiguino; Abdelkrim Khattabi; Moulay Mustapha Ennaji
Journal:  Med Oncol       Date:  2014-12-12       Impact factor: 3.064

2.  Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.

Authors:  Hanaa Skhoun; Mohammed Khattab; Aziza Belkhayat; Zahra Takki Chebihi; Youssef Bakri; Nadia Dakka; Jamila El Baghdadi
Journal:  Mol Biol Rep       Date:  2022-06-15       Impact factor: 2.742

3.  Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women.

Authors:  Zineb Qmichou; Meriem Khyatti; Mohamed Berraho; My Mustapha Ennaji; Laila Benbacer; Chakib Nejjari; Noureddine Benjaafar; Abdellatif Benider; Mohammed Attaleb; Mohammed El Mzibri
Journal:  BMC Infect Dis       Date:  2013-08-16       Impact factor: 3.090

4.  HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study.

Authors:  Mohamed Berraho; Afaf Amarti-Riffi; Mohammed El-Mzibri; Rachid Bezad; Noureddine Benjaafar; Abdelatif Benideer; Noureddine Matar; Zinab Qmichou; Naima Abda; Mohammed Attaleb; Kaoutar Znati; Hind El Fatemi; Karima Bendahhou; Majdouline Obtel; Abdelhai Filali Adib; Simone Mathoulin-Pelissier; Chakib Nejjari
Journal:  BMC Cancer       Date:  2017-06-20       Impact factor: 4.430

5.  Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta-analysis.

Authors:  Song Fan; Zong-Yao Hao; Meng Zhang; Chao-Zhao Liang
Journal:  Chronic Dis Transl Med       Date:  2017-05-25

Review 6.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.